Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29852620 | 1.00 | MAPT (0.54) | MAPTKDM4ECYP3A4LMNAAXL | |
| SCHEMBL8624 | 0.88 | CYP3A4 (0.49) | MAPTKDM4ECYP3A4LMNAAXL | |
| Imidazole SCHEMBL144265 | 0.88 | CYP3A4 (0.42) | MAPTKDM4ECYP3A4LMNAAXL | |
| SCHEMBL13166532 | 0.86 | CYP3A4 (0.47) | MAPTKDM4ECYP3A4LMNAAXL | |
| SCHEMBL146383 | 0.81 | CYP3A4 (0.44) | MAPTKDM4ECYP3A4LMNAAXL | |
| Quinoline SCHEMBL10490755 | 0.80 | ALDH1A1 (0.52) | MAPTKDM4ECYP3A4LMNAAXL | |
| SCHEMBL31358268 | 0.80 | CYP3A4 (0.43) | MAPTKDM4ECYP3A4LMNAAXL | |
| Fluoride SCHEMBL28071548 | 0.80 | CYP3A4 (0.43) | MAPTKDM4ECYP3A4LMNAAXL | |
| SCHEMBL29190842 | 0.80 | CYP3A4 (0.43) | MAPTKDM4ECYP3A4LMNAAXL | |
| SCHEMBL27715530 | 0.80 | CYP3A4 (0.43) | MAPTKDM4ECYP3A4LMNAAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1885 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3185329-B1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2026-04-22 | — | — | EP | claimed |
| US-20260059937-A1 | LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND, ELECTRONIC APPARATUS AND ELECTRONIC EQUIPMENT EACH INCLUDING THE SAME, AND THE CONDENSED CYCLIC COMPOUND | SAMSUNG DISPLAY CO LTD (KR) | 2026-02-26 | — | — | US | claimed |
| US-20250380610-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2025-12-11 | — | — | US | claimed |
| EP-4638448-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND CASEIN KINASE (CK1) INHIBITORS AND METHODS OF USE THEREOF | Bright Angel Therapeutics Inc. (CA) | 2025-10-29 | — | — | EP | claimed |
| US-12448389-B2 | BRM targeting compounds and associated methods of use | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-10-21 | — | — | US | claimed |
| US-20250313818-A1 | CRISPR-Cas Effector Polypeptides and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-10-09 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250066799-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2025-02-27 | — | — | US | claimed |
| WO-2025041085-A1 | DUAL NUCLEASE SYSTEMS FOR GENE EDITING, METHODS OF PRODUCING AND USING SAME | SPECIFIC BIOLOGICS INC. (CA) | 2025-02-27 | — | — | WO | claimed |
| US-12215343-B2 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-04 | — | — | US | claimed |
| EP-4041249-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | The Scripps Research Institute (US) | 2022-08-17 | — | — | EP | claimed |
| US-20220243244-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | NATIONAL INSTITUTES OF HEALTH | 2022-08-04 | — | — | US | claimed |
| US-11401532-B2 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-02 | — | — | US | claimed |
| CN-114761026-A | Compositions and methods for in vivo synthesis of non-native polypeptides | 斯克利普斯研究所 | 2022-07-15 | — | — | CN | claimed |
| CN-109912592-B | Compound containing pyridoindole and application of compound in organic electroluminescent device | 江苏三月科技股份有限公司 | 2022-05-17 | — | — | CN | claimed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | claimed |
| WO-2022097070-A1 | GENE EDITING WITH A MODIFIED ENDONUCLEASE | SPECIFIC BIOLOGICS INC. (CA) | 2022-05-12 | — | — | WO | claimed |
| US-11274318-B2 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-15 | — | — | US | claimed |
| EP-3560917-A1 | POLYMER CONTAINING FURAN CROSSLINKING GROUP AND USE THEREOF | Guangzhou Chinaray Optoelectronic Materials Ltd. (CN) | 2019-10-30 | — | — | EP | claimed |
| US-6472402-B1 | Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives | NEUROGEN CORPORATION | 2002-10-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250380610-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | LEF1, L1CAM, EMC1 | MAPT 2447/4885KDM4E 1399/4885CYP3A4 1253/4885 |
| US-20250066799-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | RNGTT, SPOUT1, NPEPPS | MAPT 3580/4885KDM4E 4046/4885CYP3A4 4881/4885 |
| US-20260059937-A1 | LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND, ELECTRONIC APPARATUS AND ELECTRONIC EQUIPMENT EACH INCLUDING THE SAME, AND THE CONDENSED CYCLIC COMPOUND | SCO2, CCNE2, RER1 | MAPT 4598/4885KDM4E 3927/4885CYP3A4 1530/4885 |
| US-12448389-B2 | BRM targeting compounds and associated methods of use | ADRM1, BRDT, RBX1 | MAPT 1598/4885KDM4E 2075/4885CYP3A4 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.